Bioactivity assays The cytolytic activity was assessed in a 4-h51Cr-release assay in which effector cells NKL, NK-92, freshly isolated NK or cd cytotoxic T lymphocytes were mixed with di
Trang 1Mistletoe viscotoxins increase natural killer cell-mediated
cytotoxicity
Julie Tabiasco1, Fre´de´ric Pont2, Jean-Jacques Fournie´1and Alain Vercellone1
1
Institut National de la Sante´ et de la Recherche Me´dicale U563 and2Service de spectrome´trie de masse de l¢ IFR 30,
CHU Purpan, BP3028, Toulouse, France
Mistletoe extracts have immunomodulatory activity We
show that nontoxic concentrations of Viscum album extracts
increase natural killer (NK) cell-mediated killing of tumor
cells but spare nontarget cells from NK lysis The
com-pounds responsible for this bioactivity were isolated from
mistletoe and characterized They have low molecular mass
and are thermostable and protease-resistant After complete
purification by HPLC, they were identified by tandem MS as
viscotoxins A1, A2 and A3 (VTA1, VTA2 and VTA3,
respectively) Whereas micromolar concentrations of these
viscotoxins are cytotoxic to the targets, the bioactivity with respect to NK lysis is within the nanomolar range and differs between viscotoxin isoforms: VTA1 (85 nM), VTA2 (18 nM) and VTA3 (8 nM) Microphysiometry and assays of cell killing indicate that, within such nontoxic concentrations, viscotoxins do not activate NK cells, but act on cell conju-gates to increase the resulting lysis
Keywords: mistletoe; natural killer cells; tumor cells; visco-toxin; Viscum album
Mistletoe preparations have been used for pharmacological
purposes since ancient times [1] These days, industrially
produced extracts from mistletoe are used in treatments of
solid tumors [2–5] It is thought that the molecular basis of
the antitumoral activity of mistletoe lies in several distinct
bioactivities First, its lectin content is responsible for direct
toxicity to tumor cells [6–9] Secondly, the Viscum album
rhamnogalacturonan oligosaccharide favors bridging of
natural killer (NK)–tumor cell conjugates, enhancing
effi-ciency of killing [10–15] Thirdly, it has been found that the
antitumoral human cytotoxic T lymphocytes with cd T cell
receptor are selectively activated by mistletoe ligands of
phosphoantigen structure [16,17]
NK cells play an important role in antitumoral immunity
as they directly kill tumor cells and regulate the adaptative
immunity [18] Activation of cytolytic functions of NK cells
relies mainly on selective interactions of NK receptors with
major histocompatibility complex (MHC) class I-related
molecules on the tumoral cells Distinct ligands, however,
may also induce NK cell stimulation [19–23] Hence,
immunotherapeutic modulation of NK cell activation is
an important issue in current antitumoral approaches
We analysed the bioactivity of V album compounds in
the in vitro killing of tumor cells by human NK cells and
found that the components that mediate this bioactivity are
viscotoxins
M A T E R I A L S A N D M E T H O D S Preparation ofV album (Va) extract The green and white parts of mistletoe (V album L., Viscaceae; 1 kg) freshly collected on Robinia pseudacacia L were crushed and extracted twice with 5 L methanol/water (1 : 1, v/v) After filtration and volume reduction to
600 mL, the aqueous phase was successively partitioned with cyclohexane, dichloromethane and ethyl acetate This aqueous phase was positive in tests of enhancement of NK-mediated killing of tumor cells, but was directly toxic for the tumor target cell line Ethanol was added to the concentrated aqueous phase to achieve 85% (v/v) concen-tration A precipitate was obtained and separated from the supernatant by centrifugation (2000 g; 10 min) The super-natant was concentrated and ethanol was added to 85% (v/v) After centrifugation, the precipitate was dissolved in water, pooled with the former precipitate, and constituted the Va extract The final yield of Va extract was 50 g from
1 kg plant extracted The stock solution of Va extract (237 mgÆmL)1) was stored at)20 C
Viscotoxins The protocol for purifying viscotoxins was modified from a previous method [24,25] Briefly, to fractionate Va extract,
we replaced ion-exchange and exclusion chromatography with C18 reverse-phase open column chromatography to avoid the use of salt solutions A 4-g portion of Va extract was applied to a column (2.5· 20 cm) of Lichroprep RP-18 (Merck, Darmstadt, Germany), which was irrigated with
300 mL 20%, 40% and 100% acetonitrile in 0.1% aqueous acetic acid The former 40% acetonitrile eluate was freeze-dried, dissolved in 20% acetonitrile in 0.1% trifluoroacetic acid and chromatographed by C18 reverse-phase HPLC (Nucleosil 5 lm; 300 A˚ pore size; Bischoff, Leonberg, Germany) The column (250· 4.6 mm) was eluted at
Correspondence to: A Vercellone, INSERM U395, CHU Purpan,
BP 3028, 31024 Toulouse, France.
Fax: 335 6274 8386, Tel.: 335 6274 8364,
E-mail: vercello@toulouse.inserm.fr
Abbreviations: MHC, major histocompatibility complex; MSn,
multiple-stage MS; NK, natural killer; VTA, viscotoxin A; TNF-a,
tumor necrosis factor a.
(Received 28 November 2001, revised 27 March 2002,
accepted 15 April 2002)
Trang 21 mLÆmin)1 by a linear gradient from 20% to 50% of
acetonitrile in 0.1% trifluoroacetic acid over 30 min For
final purification of VTA2 and VTA3, the elution was
carried out with the following gradient: 25% solvent B
(acetonitrile in 0.1% trifluoroacetic acid) and 75% solvent
A (0.1% aqueous trifluoroacetic acid) during the first
10 min, 1 min up to 30% solvent B, 9 min with 30% solvent
B, and from 30% up to 40% over 5 min Cation-exchange
chromatography was conduced on a polypore SP 10 micron
(100· 2.1 mm) column (Applied Biosystems) using linear
gradient elution at 0.3 mLÆmin)1 from 100% solvent A
(50 mMphosphate buffer, pH 7) to 100% solvent B (1M
NaCl in 50 mM phosphate buffer, pH 9) in 30 min The
VTA3 standard was kindly provided by K Urech and
purified as described by Schaller et al [24]
Chemical and enzymatic treatments
Dilution in organic solvent was achieved by addition of pure
acetonitrile to 80% final volume After 2 h at room
temperature, organic solvent was removed by evaporation
with a Speed-vac centrifuge before further bioassays For
chemical treatments, 1 vol Va extract or purified viscotoxin
was mixed with 1 vol 4M NaOH or 4M HCl and
incubated for 2 h at 37C After neutralization with HCl
or NaOH, the samples were immediately diluted in RPMI
medium supplemented with 10% human serum, and pH
was adjusted to 7.0 before further bioassays For periodate
oxidation, sodium periodate (Sigma) was added (final
concentration 5 mM) to the Va extract or to purified
viscotoxin, and samples were left for 2 h at room
tempera-ture Unchanged sodium periodate was further neutralized
by the addition of a few drops of glycerol to the sample
Reduction and alkylation were performed as described
previously [26] Excess reagent was removed by purification
on a tC18 September–Pak cartridge (Walters, Milford,
MA, USA) eluted successively with increasing percentages
of acetonitrile
Enzymatic treatments consisted of incubating Va extract
for 2 h at 37C with proteinase K (1.5 UÆmL)1; Boehringer,
Mannheim, Germany), calf alkaline phosphatase
(1 UÆmL)1; Boehringer), or sulfatase (16.8 UÆmL)1
Aeromonas aerogenes sulfohydrolase; Sigma) in 10 mM
Tris/HCl, pH 7.2 Heating at 75C for 10 min stopped
enzymatic reactions before further bioassay
SDS/PAGE
SDS/PAGE analysis of Va extract and viscotoxins was
performed using 7· 10 cm gels of 20% acrylamide (37.5 : 1
ratio of acrylamide to bisacrylamide) for the resolving gel
and 5% acrylamide for the stacking gel Samples were
electrophoresed at 75 V, and further stained by Coomassie
Blue or silver nitrate
Mass spectrometry
MS was performed using the LCQ Ion-trap mass
spectro-meter (Thermo-Finnigan, San Jose´, CA, USA) by liquid
chromatography/MS and nanospray as described [27] The
viscotoxin masses were obtained by spectral deconvolution
with Bioworks software from the Xcalibur 1.2 suite
(Thermo-Finnigan) Multiple stage MS (MSn) sequencing
of viscotoxins was carried out on the underivatized sample The peak at m/z 966.5 (i.e z ¼ + 5 for VTA2 for which the mass is ¼ 4827 Da) was selected in full-scan MS and fragmented In its MS2spectrum, Y ions corresponding to the disulfide-free C-terminal moiety of VTA2 were selected and fragmented by MS3 Fragmentation of the Y6ion (m/z 706.3) led to overlapping sets of Y and bions identifying the six C-terminal amino acids of VTA2 The precision of this experiment did not allow lysine to be distinguished from glutamine
Cell lines and cultures Peripheral blood lymphocytes were obtained from hepari-nized venous blood of healthy volunteers using Ficoll-Paque (Amersham Pharmacia Biotech AB, Uppsala, Sweden) Fresh NK cell populations were obtained by peripheral blood lymphocyte depletion of non-NK cells using the NK Cell Isolation Kit (Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany) The phenotype of isolated cells was analyzed by flow cytometry with CD16 mAb and CD56 mAb(clone 3G8 and N901-NKH1, respectively; Immuno-tech-Beckman-Coulter, Marseilles, France) The resulting
NK population typically comprised more than 85% of CD56 cells and less than 0.5% CD3 cells The different human cell targets (K562, an MHC class I-deficient mono-myelocytic tumor [28]; Daudi, a b2m–Burkitt’s lymphoma cell line [29]; Val, a non-Hodgkin B cell lymphoma [30]; C1R, a lymphoblastoid tumor expressing only the HLA class I allele Cw 0401 [31]; and C1R-B27 [32]) were maintained in culture in complete RPMI 1640 medium with Glutamax-I supplemented with 10% fetal calf serum (Gibco–BRL, Life Technologies, Cergy Pontoise, France) The murine FccR+ mastocytoma P815 cell line was maintained in complete Dulbecco’s modified Eagle’s culture medium (Sigma Aldrich, St Louis, MO, USA) supplemen-ted with 5% human serum The human interleukin-2-dependent NK cell lines NKL [33] and NK-92 [34] (kindly provided by E Vivier, CIML, Marseilles, France) were maintained in RPMI 1640 medium with Glutamax-I (Gibco–BRL) supplemented, respectively, with 10% pooled human AB serum plus recombinant interleukin-2 (100 UÆmL)1; Chiron) and 10% fetal calf serum plus recombinant interleukin-2 (200 UÆmL)1) The cd cell line has been described previously [27]
All the culture media were complemented with
100 UÆmL)1 penicillin, 100 UÆmL)1 streptomycin and
1 mMsodium pyruvate (all from Gibco–BRL)
Bioactivity assays The cytolytic activity was assessed in a 4-h51Cr-release assay
in which effector cells (NKL, NK-92, freshly isolated NK or
cd cytotoxic T lymphocytes) were mixed with different target cells Lysis assays were carried out with or without Va fractions added at different concentrations Briefly, 106 target cells were labeled with 100 lCi sodium [51 Cr]bichro-mate (10 mCiÆmL)1; ICN) at 37C for 1 h The cells were then washed three times with RPMI and added to the effector cells at 3· 103cells/well in 96-well round-bottom microplates, resulting in an effector to target cell (E/T) ratio ranging from 30 : 1 to 3 : 1 in a final volume of 0.2 mL in each well For the redirected killing assay, target cells were
Trang 3the (FccR+) P815 cell line, and effector cells the CD16+
NKL cell line, using an E/T ratio of 3 : 1 The assays were
carried out with or without 2 lgÆmL)1 anti-CD16 IgG1
(clone 3G8) After 4 h of incubation at 37C, 100 lL
supernatant was harvested and counted in the gamma
counter The percentage specific 51Cr release was
deter-mined from the relation:
[(experimental c.p.m.) spontaneous c.p.m.)/(total c.p.m
incorporated) spontaneous c.p.m.)] · 100
All determinations were performed in triplicate in each
assay, and results shown are the mean ± SEM from
triplicate determinations of a representative experiment out
of five independent experiments (on average) For clarity,
SEMs are not represented on most of the figures because
they were below 3% of specific lysis
Release of tumor necrosis factor a (TNF-a) was
meas-ured b y a b ioassay using TNF-a-sensitive cells
(WEHI-13VAR, ATCC CRL-2148) Briefly, 5· 104NKL cells per
well were incubated for 24 h at 37C with or without
various concentrations of each viscotoxin in 100 lL culture
medium A 50-lL portion of supernatant was then added to
50 lL WEHI cells plated at 3· 104cells per well in culture
medium containing actinomycin D (2 lgÆmL)1) and LiCl
(40 mM) WEHI cells were incubated for 20 h at 37C
Viability of WEHI cells was then measured with a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(Sigma) assay Levels of TNF-a release were then calculated
from a standard curve obtained using purified human
recombinant TNF-a (PeproTech, Inc., Rocky Hill, NJ, USA) Typically, unstimulated NKL cells release
5 ± 2 ngÆmL)1 TNF-a compared with 60 ± 5 ngÆmL)1 when induced by phorbol myristate acetate (4 ngÆmL)1) and ionomycin (500 ngÆmL)1)
To probe for soluble cytolytic factors released by NK cells during the lysis assay, 9· 104 NK cells were mixed with 3000 K562 cells and incubated with viscotoxins for 4 h
at 37C A 100-lL portion of supernatant was then added
to 300051Cr-labeled K562 cells plated in a 96-well round-bottom microplate After 4 h incubation at 37C, 100 lL supernatant was collected and counted in a gamma counter The percentage of specific51Cr release was determined as for the cytotoxicity assay
R E S U L T S Nontoxic concentrations of Va extract enhance NK cell-mediated and antibody-redirected lysis
A crude hydrosoluble extract was prepared from crushed mistletoe leaves, and added to in vitro lysis assays with K562 tumor targets and various NK effector cells As indicated by the spontaneous release of51Cr from target cells alone, Va extract diluted 1 : 5000 was not directly toxic for these targets On the other hand, Va extract increased K562 lysis
by freshly isolated NK cells or by a strongly cytolytic cd T cell line [35] NK cell lysis in the presence of Va extract was
Fig 1 V album extract (VaE) enhances
cytolytic activity of different killer cells for
various target cells (A) Lysis of K562 target
cells by the following effector cells: fresh NK
cells, cd cytotoxic T lymphocytes, NKL, and
NK-92 titrated at different E/T ratios, in the
presence (d) or absence (s) of Va extract
diluted 1 : 5000 in all assays Shown on the
right of each lysis assay are the c.p.m of
spontaneous51Cr release by the target cells
alone (target spontaneous release) incubated
under the same conditions in the presence
(filled bars) or absence (empty bars) of Va
extract diluted 1 : 5000 in all assays Each
result represents the mean of triplicate
experi-ments (B) NKL effectors were tested for
kill-ing of the target cells lines, C1R, C1R-B27,
Daudi and Val, at different E/T ratios, in the
presence (d) or absence (s) of Va extract
diluted 1 : 5000 Shown on the left of each
cytotoxic experiment are the c.p.m of
spon-taneous 51 Cr release by the target cells alone as
above (C) NKL cells were tested in a
redi-recting killing assay against the FccR+P815
target cells These assays were carried out in
the absence or presence of CD16 mAb
(2 lgÆmL)1) and with or without Va extract
(VaE) diluted 1 : 5000 Each result represents
the mean of triplicate experiments at an E/T
ratio of 3 : 1.
Trang 4equivalent to four times the number of killer cells when
present alone (Fig 1A) Similar results were found with two
other NK cell lines, NK-92 and NKL Thus nontoxic
concentrations of Va extract increased NK lysis
NK cells eliminate tumor cells in the absence of
appropriate interactions between their inhibitory receptors
and MHC class I molecules on the surface of the target cells
Thus we investigated whether Va extract would alter the
lysis of target cells other than K562 by the cell line NKL Va
extract also enhanced killing of the HLA class I-deficient
targets C1R and Daudi (Fig 1B) However, Va extract did
not trigger killing of the HLA class I cells Val or C1R-B27, a
C1R cell line transfected with the HLA-B27 allele protecting
against lysis by NKL cells [33]
NK cells may also lyse IgG-bound tumor cells [36], so we
investigated whether Va extract was also bioactive in this
case Lysis of the FccRIII+cells P815 by NKL cells in the
presence of CD16 mAb[37] was measured with and without
Va extract Again, Va extract was not directly toxic to P815
cells but enhanced its antibody-redirected killing (Fig 1C)
Therefore, the bioactivity of this Va extract appears to be
independent of the NK-lysis activation pathway
Bioactivity-guided isolation of thermostable
and low-molecular-mass proteins from Va extract
Bioactivity of Va extract in NKL cells could be titrated in
lysis assays by varying the E/T ratio and Va extract
concentrations (Fig 2A) This helped to guide the isolation
of the molecule(s) responsible After various treatments of
Va extract, titration of the remaining bioactivity indicated that the bioactive component(s) were resistant to heating, acid, protease, phosphatase and sodium periodate (Ta-ble 1) This suggested that the molecule was thermosta(Ta-ble, although presumably neither a protein nor a carbohydrate, despite their relative abundance (carbohydrate content
10 mgÆmL)1; data not shown) in Va extract revealed by silver nitrate and Coomassie Blue staining of SDS/poly-acrylamide gels (Fig 2B) However, bioactivity in the Va extract was degraded by alkali or a reduction–alkylation treatment that targeted disulfide bridges (Table 1) Further isolation of the NK-bioactive compound(s) was based on HPLC with macroporous reverse-phase support (Fig 2C) Bioassay-guided fractionation of the Va extract indicated that the bioactivity was due to distinct UV-absorbing peaks split into two consecutive HPLC fractions The HPLC fractions 14–17 min and 17–20 min increased the NKL-mediated lysis of K562 cells (Fig 2C) With regard to the specific NK lysis, no other bioactive fraction could be recovered by this procedure Both absorbance characteris-tics of the active fractions (not shown) and their appearance
on SDS/PAGE (Fig 2B) revealed that they comprised small protein(s) with estimated molecular mass of 5 kDa
The only Va extract molecules bioactive in NK lysis are VTA1-3
On the one hand, proteins were unexpected for the unusual thermostability and protease-insensitivity of the bioactive extract, but, on the other hand, they could account for the
Fig 2 NKcell lysis bioassay-guided isolation
of viscotoxins (A) Cytolytic activity of NKL cells against K562 target cells with Va extract diluted 1 : 5000 (j), 1 : 15 000 (m), 1 : 45 000 (e) or without Va extract (s) (B) SDS/ PAGE of Va extract and fraction 17–20 min (VT) stained with either AgNO 3 or Coomassie Blue (C) RP-HPLC separation of bioactive fractions from the Va extract monitored for total ion current and for bioactivity on NKL cells Fractions were collected every 3 min, lyophilized, and tested in the NKL/K562 killing assay as above Online coupling of HPLC to ion trap electrospray ionization MS was used to identify viscotoxins at the specified peaks.
Trang 5sensitivity to disulfide-specific reaction (Table 1) To
unam-biguously identify these molecules, we used online coupling
of the above HPLC separation with ion-trap MS detection
(liquid chromatography/MS) Using positive-mode
electro-spray, analysis of the HPLC peaks gave a series of
multicharged ion species (not shown) that were further
deconvoluted in the 2000–6000 mass range The
deconvo-lution spectrum of the major peak from bioactive fraction
17–20 min gave two molecular species of 4827.0 and
4925.0 Da (Fig 3A) They correspond, respectively, to the
expected molecular mass of VTA2 (theoretical mass 4828.4) and to a noncovalent phosphate adduct of VTA2 [25] Similar analysis of the other bioactive HPLC peaks identified VTA1 (mass 4884.0) and VTA3 (mass 4830.0) (Fig 2C and [25]) This conclusion was checked by partial peptide sequencing using MSn As the N-terminal moiety of native viscotoxins involves a disulfide bridge [25], sequential fragmentation of each C-terminal moiety was performed to confirm these assignments From native VTA2, we selected
b y MS2two ions belonging to the Y series (m/z 407, 706.3) (data not shown) Its fragmentation into the expected Y-type and b-type fragments characterized the C-terminal PSDYPK hexapeptide sequence (Fig 3B) Similar experi-ments established the identity of VTA1 and VTA3 (data not shown)
The HPLC fraction eluted at 17–20 min was dried and weighed, and, although its bioactivity in NK-mediated killing was clear-cut, it still comprised a mixture of distinct viscotoxins The same reverse-phase HPLC procedure was repeated, but using a slower elution sequence This resulted
in resolution into three peaks corresponding to each of the three distinct viscotoxins Each of the separated viscotoxins was then individually controlled chromatographically by reverse-phase (Fig 4A) and cation-exchange (Fig 4B) chromatography Parallel bioactivity monitoring of these runs revealed that NK lysis activity was recovered with each
of the purified viscotoxin peaks A molecular mass of
4884 Da identified VTA1 in the first bioactive fraction (not shown), a molecular mass of 4827 Da identified VTA2 in the second bioactive fraction (Fig 4A), and a molecular mass of 4830 Da (and 4928 Da for the phosphate adduct) identified VTA3 in the third bioactive fraction (Fig 4A) The bioactivities of VTA1–3 were destroyed by alkali and reduction–alkylation of disulfide bridges, but not by heat or periodate, as described above for Va extract (Table 1) So, this profile establishes the involvement of VTA1–3 as the only components of Va extract that enhance NK lysis Moreover, the fact that polymyxin B (10 lgÆmL)1) did not affect the bioactivity of the purified viscotoxins ruled out any contribution of traces of lipopolysaccharide to the observed effect (not shown)
Table 1 NKbioactivity of Va extract and purified viscotoxins after
chemical and enzymatic treatments The NK lysis-increasing bioactivity
was normalized to 100% using the largest increase in lytic response in
the presence of untreated Va extract (here + 22% of specific K562
lysis), VTA1 (here + 16%) or VTA2 (here + 20%) For comparison,
the NK lysis-increasing bioactivity of chemically treated extracts is
expressed as a percentage of the reference bioactivity Va extract,
VTA1 and VTA2 were used at 1 : 5000 dilution, 100 n M and 40 n M ,
respectively, which had no direct toxicity for K562 cells NT, Not
tested; DTT, dithiothreitol; IEt, iodoethanol.
Treatment
NK bioactivity (%)
Va extract VTA1 VTA2
Heat (75 C, 2 h) 91 74 88
Dilution in organic solvent
(80% acetonitrile)
73 100 100 Acid
(2 M HCl, 2 h, 37 C)
Alkali
(2 M NaOH, 2 h, 37 C)
Periodate oxidation
(5 m M NaIO 4 , 2 h, 20 C)
100 91 120 Reduction + alkylation
(DTT, IEt)
Proteinase K 90 NT NT
Alkaline phosphatase 77 NT NT
Fig 3 Biochemical identification of the
visco-toxin A2 (A) Deconvoluted spectrum from
the electrospray ionization MS analysis of the
VTA2 peak corresponds to the expected mass
of VTA2 The amino-acid sequence with
disulfide bridges of VTA2 is shown on the
right [25] (B) MS3spectrum of the ion at m/z
706.3 generated from pentacharged VTA2
(m/z 966.6) The sequence of the C-terminal
moiety and assignment of the fragmentation
series are indicated.
Trang 6Using SDS/PAGE examination of serial Va extract
dilutions, we estimated the total viscotoxin concentration in
the Va extract to be 3 mM This estimate is in
concor-dance with the respective bioactivities measured above for
purified viscotoxin and Va extract
Each purified viscotoxin species was quantified by analytical HPLC, and its bioactivity in the NKL/K562 assay titrated by serial dilutions As each of the viscotoxin samples produced similar increases in NK lysis, we compared the three viscotoxins by determining their respective EC50values, i.e the VTA concentration produ-cing half-maximal increase in NK-mediated lysis These
EC50 values are significantly different: 85 ± 6.4 nM for VTA1, 18 ± 4.2 nMfor VTA2 and 8 ± 3.0 nMfor VTA3 (two-by-two comparison, highest two-tailed P value for statistical difference equalled 0.0284) These findings matched that of an authentic VTA3 standard [24], which enhanced NK-mediated lysis with EC50 ¼ 6.5 ± 3.5 nM without direct cytotoxicity within the 1–100 nM range (Fig 5) This reference VTA3 EC50value was not signifi-cantly different from that of the VTA3 (P ¼ 0.6031) purified in this study Together these data confirm that viscotoxins are the Va extract compounds responsible for the increase in NK cell-mediated cytotoxicity
VTA2 acts on NK–target cell conjugates The interaction between NK and target cells successively involves the formation of conjugates, the specific recogni-tion phase, and the lethal hit delivery Afterwards, the killer cells are recycled and may serially kill several targets [38] Because the action of viscotoxin was found to be independ-ent of the NK activation pathway (Fig 1), we investigated
Fig 5 Effect of a VTA3 standard on NK-mediated lysis in the absence
of direct cytotoxicity Lysis of K562 target cells by NK cells at E/T ratio
of 1 : 1 in the absence (0) or presence of pure VTA3 standard (kindly
provided by K Urech [24]) added in the concentration range 0–100 n M
to the culture wells (up) Toxicity of VTA3 for the target cells alone
was titrated over the same concentration range as above by
measure-ment of the direct51Cr release from pulsed K562 cells (down) Each
result represents the mean of triplicate experiments.
Fig 4 Biochemical characterization of the purified viscotoxins A1, A2 and A3 (A) RP-HPLC and (B) cation-exchange HPLC of purified viscotoxins A2 and A3 monitored for absorbance at 220 nm and for bioactivity on NKL cells Fractions delimited by tick marks were collected, lyophilized, and tested in the NKL/K562 killing assay The deconvoluted mass spectrum of each purified viscotoxin is shown in the inset.
Trang 7whether a viscotoxin pulse of either NKL effector or K562
target cells before the assay could also lead to this
bioactivity Neither VTA2-pulsed killers nor VTA2-pulsed
targets alone reproduced the bioactivity of viscotoxins in the
usual lytic assay (Fig 6A) Therefore, to exert its
bioactiv-ity, viscotoxin must be present during the killing assay
Moreover, viscotoxins did not induce production of soluble
toxic factors by NKL cells during the 4-h incubation with
target cells (data not shown; see Materials and methods)
These results indicate that VTA2 acts on NK–target cell
conjugates
From cell mixing to final cell harvest, these cytotoxicity
assays span 4 h, so we determined viscotoxin bioactivity
when added at various time points The optimum for VTA2
bioactivity was when it was added 30–45 min after cell
contact (Fig 6B) When compared with other drugs
targeting NK activation [39], this time-course suggests that
VTA2 affected an event subsequent to conjugate formation,
in agreement with the former conclusion
VTA2 does not activate NK cells
NK–target cell conjugation precedes NK cell activation,
which follows a complex array of activatory and inhibitory
receptor–ligand interactions In hematopoietic cells, intra-cellular transduction of activation signals involves changes
in metabolic rates, which may be detected by micro-physiometry [27] As Va extract acts on both redirected and natural lysis by NK cells (Fig 1), its effects appear to be independent of the NK activation pathway Therefore, viscotoxins were not expected to directly activate NK cells
To address this issue, we tested microphysiometric responses
of NKL cells to VTA2 Although a short pulse with the mitogen combination of phorbol ester and ionomycin increased the metabolic rate of NKL cells (Fig 6C), no such change was detected in parallel assays with NK cells exposed to various concentrations of VTA2 alone (shown for 50 nM in Fig 6C) or to phorbol and VTA2 together (data not shown) So VTA2 does not constitute an activator signal to NK cells nor bring them a cosignal additional to phorbol esters This conclusion was also supported by the finding that NKL cells incubated with VTA2 alone did not produce any more TNF-a than unstimulated ones (data not shown)
After killer–target cell binding and NK cell activation, early intracellular events involved in NK-mediated lysis comprise polarization and delivery of cytotoxic granules
at the target cell synapse We investigated whether the
Fig 6 VTA2 acts on NK–target cell conjugates without a change in extracellular acidification rate of NK cells and killing of bystander cells (A) Enhancement of NK cytotoxicity cannot be reproduced by a VTA2 pulse of effector or target cells before the lysis assay The effector cells or target cells were separately preincubated with 50 n M VTA2 for 4 h and washed before running the usual cytotoxic assay without VTA2 For comparison, the same assay was run without preincubation and with or without VTA2 during the killing assay (B) Time course of VTA2 bioactivity in the killing assay At t ¼ 0 min, effector and target cells were mixed At the times indicated, 50 n M VTA2 (final concentration) was added, and 4 h after mixing of the cells, specific51Cr release was determined For each time point, viscotoxin bioactivity was calculated as follows: (% of specific lysis with VT) ) (% of specific lysis without VTA2) For each time point, the viscotoxin bioactivity was normalized using the largest increase found with viscotoxin in the assay (+15% at t ¼ 30 min; s) For comparison, the time course of bioactivity of ion channel blockers was plotted (d) as described by Sidell et al [39] (C) NKL cells in microphysiometer chambers were drained with complete medium only (n), with complete medium containing phorbol myristate acetate + ionomycin (m) or with complete medium containing 50 n M VTA2 (s) For 80 min, extracellular acidification was monitored every 90 s in each chamber, and the response was normalized to the rate value before sample introduction (D) Bioactivity of VTA2 was tested in a three-cell lysis assay involving NKL killer, K562 target and C1R-B27 bystander cells While the presence of bystander cells did not interfere with viscotoxin bioactivity in the killing assay (left), VTA2 did not induce any detectable killing of 51 Cr-labeled bystander cells (right).
Trang 8killing-enhancing bioactivity of VTA2 resulted from altered
polarization of lytic granules in such a way as to kill
bystander cells in addition to bound targets NKL cells were
simultaneously exposed to K562 target cells and C1R-B27
bystander cells (one target for one bystander mixed
together) We then measured the effect of VTA2 on either
lysis of51Cr-labeled K562 target cells in the presence of
bystanders, or reciprocally, on lysis of51Cr-labeled
C1R-B27 bystanders in the presence of K562 target cells VTA2
was devoid of direct toxicity to the bystander cells while
simultaneously being bioactive against the NK targets
(Fig 6D)
So, whereas VTA2 enhances killing of K562 target cells in
the presence of bystanders, it does not induce further
collateral lysis and hence does not affect the polarization of
the cytolytic activity of NK cells
D I S C U S S I O N
The lytic activity of human NK cells is enhanced by
V album compounds [10,40,41] Previous studies have
investigated this effect using fermented Va extracts,
peripheral blood lymphocytes, and cytokine-dependent
and lymphokine-dependent contexts [13,15,42] The
results presented here indicate that the lysis of K562
cells by either freshly isolated NK cells or the tumoral
NK cell lines NK-92 and NKL is increased by the
presence of Va extract molecules in the lytic assay The
lytic potential of killer cells in the presence of the extract
was almost the same as that of four times as many killer
cells alone This effect of Va extract is not restricted to
NK cells, as other types of cytotoxic T lymphocyte, such
as cd T cells, that exert strong NK-like activity against
the same targets are also enhanced b y these molecules
So we investigated the V album-mediated enhancement
of killing by NK cells independently of exogenous
cytokine supply
In previous studies, the V album molecules bioactive in
tumor cell killing by NK cells and monocyte/macrophages
were identified as oligosaccharides (arabinogalactan [11] or
rhamnogalacturonan [12,43]), which link killer and target
cells [43] This report describes the isolation and
identifica-tion of VTA1, VTA2 and VTA3 as the only Va extract
component of NK-cell-mediated lysis Mistletoe produces
two protein families with related biological properties:
lectins and viscotoxins [44,45] Viscotoxins are a group of
highly basic cysteine-rich small proteins related to the family
of thionins [46] and notoriously resistant to
protein-denaturing agents [45,47] Table 1 shows that the starting
bioactivity of the Va extract has such characteristics Other
workers had already reported an uncharacterized
Va-derived peptide that activated NK cells in vivo [48] Thionins
are cytotoxic for a large variety of eukaryote and
proka-ryote cells [49] This toxicity relies on positive charges of
thionins interacting unspecifically with phospholipids Thus,
by passive insertion into the cell membranes, thionins
permeabilize and kill tumoral cells [49,50] Few studies have
in fact elucidated the basis of viscotoxin toxicity Using the
most viscotoxin-sensitive cell line [51], micromolar
concen-trations of viscotoxins are toxic for the rat renal sarcoma
Yoshida [24] More recently, VTA3 has been found to
induce cell membrane stiffening and destabilization [52]
Here, the action on NK-cell-mediated killing of tumor
targets was analysed using nontoxic nanomolar concentra-tions of viscotoxin The data presented lead to clearer conclusions than earlier studies of the effect of V album on tumor cell lysis by monocytes and NK cells The synergistic enhancement of lysis by mistletoe arabinogalactan is mediated by cytokines secreted from killer cells after its binding to NK surface receptors [13,15] These cells pulsed with high concentrations of arabinogalactans killed more target cells [13,15]
Our study shows a different spectrum of effects of purified viscotoxins which appear to be focused on estab-lished killer–target cell conjugates
NK cell lysis results from intracellular integration of a wide array of receptor-mediated activatory and inhibitory signals As the absence of a lytic response could result from dominance of negative signaling by cell targets, the actual activity of viscotoxins on positive signaling pathways needed to be investigated in NK cells more directly Activation of hematopoietic cells involves increased glyco-lysis, Na+/H+ antiport, and lactate and carbonic acid excretion, which together cause medium acidification [53] Microphysiometry monitors extracellular acidification as a real-time follow-up of metabolic rate, and detected NKL response to a mitogen combination VTA2 alone does not alter the metabolic rate of NKL cells, so they do not provide
a self-sufficient positive signal for activating NK cells Furthermore, the action of VTA2 on killer–target cell couples spares the unproductive killer-bystander ones Therefore VTA2 does not alter the polarization of cytolytic activity against the activating target, nor does it weaken the latter in such a way as to increase their lysis in the assay Besides the lack of viscotoxin toxicity for the various targets cells in this study, this conclusion can be drawn from the several lines of evidence discussed below First, a pulse and rinse of targets with viscotoxins did not increase their subsequent lysis by NK cells Secondly, viscotoxins do not cause the lysis of bystander cells exposed to viscotoxins and activated NK
Investigation of the molecular basis of viscotoxin action
on NK–target cell conjugates was not within the scope of this study However, the high bioactivity of viscotoxins (i.e
in the nanomolar range) in this assay, and the differential (8–80 nM) of bioactivity between the structurally related VTA1–3 proteins strongly suggest an interaction with an unidentified receptor involved in NK lysis Viscotoxins are structurally related to thionins [46], which behave
as selective ion channels in nanomolar concentration ranges [50] As functional ion channels are involved in NK-mediated lysis [54], a related role for viscotoxins is hypothesized
Long-standing medicinal virtues have been imputed to mistletoe extracts, used in the treatment of some solid tumors Although mistletoe was thought to owe much of its bioactivity to the direct toxicity of several components
to tumoral cells, this report shows that highly purified viscotoxins alone enhance the efficiency of tumor cell lysis by NK cells in the absence of any direct cytotoxicity
to the target Although the mode of viscotoxin action has not been defined, we show that viscotoxins are involved in immunologically mediated tumour cell destruction Future studies will aim to identify the viscotoxin receptors involved in this therapeutically interesting bioactivity
Trang 9A C K N O W L E D G E M E N T S
We wish to thank E Vivier for helpful discussions and provision of cell
lines, and E Espinosa for the cd cell line We also thank Dr K Urech
for the gift of the highly purified viscotoxin A3 This work was
supported by institutional grants from INSERM and Programme
Eureka from ARC.
R E F E R E N C E S
1 Leroi, R (1977) Nachbehandlung des operierten
MammaKar-zinoms mit Viscum album Helv Chim Acta 44, 403–414.
2 Friess, H., Beger, H.G., Kunz, J., Funk, N., Schilling, M &
Buchler, M.W (1996) Treatment of advanced pancreatic
cancer with mistletoe: results of a pilot trial Anticancer Res 16,
915–920.
3 Heiny, B.M., Albrecht, V & Beuth, J (1998) Correlation of
immune cell activities and beta-endorphin release in breast
carci-noma patients treated with galactose-specific lectin standardized
mistletoe extract Anticancer Res 18, 583–586.
4 Zarkovic, N., Vukovic, T., Loncaric, I., Miletic, M., Zarkovic, K.,
Borovic, S., Cipak, A., Sab olovic, S., Konitzer, M & Mang, S.
(2001) An overview on anticancer activities of the Viscum album
extract Isorel Cancer Biother Radiopharmacol 16, 55–62.
5 Steuer-Vogt, M.K., Bonkowsky, V., Ambrosch, P., Scholz, M.,
Neiss, A., Strutz, J., Hennig, M., Lenarz, T & Arnold, W (2001)
The effect of an adjuvant mistletoe treatment programme in
resected head and neck cancer patients: a randomised controlled
clinical trial Eur J Cancer 37, 23–31.
6 Gabius, S & Gabius, H.J (1999) [Immunomodulating mistletoe
therapy by lectin standardization: a double-edged sword? (see
comments) ] Versicherungsmedizin 51, 128–136.
7 Gabius, H.J., Andre, S., Kaltner, H., Siebert, H.C., von der
Lieth, C.W & Gabius, S (1996) The mistletoe myth: claims,
reality and provable perspectives Z Arztl Fortbild (Jena) 90,
103–110.
8 Baxevanis, C.N., Voutsas, I.F., Soler, M.H., Gritzapis, A.D.,
Tsitsilonis, O.E., Stoeva, S., Voelter, W., Arsenis, P &
Papamichail, M (1998) Mistletoe lectin I-induced effects on
human cytotoxic lymphocytes I Synergism with IL-2 in the
induction of enhanced LAK cytotoxicity Immunopharmacol.
Immunotoxicol 20, 355–372.
9 Valentiner, U., Pfuller, U., Baum, C & Schumacher, U (2002)
The cytotoxic effect of mistletoe lectins I, II and III on sensitive
and multidrug resistant human colon cancer cell lines in vitro.
Toxicology 171, 187–199.
10 Hamprecht, K., Handgretinger, R., Voetsch, W & Anderer, F.A.
(1987) Mediation of human NK-activity by components in
extracts of Viscum album Int J Immunopharmacol 9, 199–209.
11 Wagner, H & Jordan, E (1988) An immunologically active
ara-binogalactan from Viscum album berries Phytochemistry 27,
2511–2517.
12 Mueller, E.A., Hamprecht, K & Anderer, F.A (1989) Biochemical
characterization of a component in extracts of Viscum album
enhancing human NK cytotoxicity Immunopharmacology 17,
11–18.
13 Mueller, E.A & Anderer, F.A (1990) A Viscum album
oligo-saccharide activating human natural cytotoxicity is an interferon
gamma inducer Cancer Immunol Immunother 32, 221–227.
14 Mueller, E.A & Anderer, F.A (1990) Synergistic action of a plant
rhamnogalacturonan enhancing antitumor cytotoxicity of human
natural killer and lymphokine-activated killer cells: chemical
spe-cificity of target cell recognition Cancer Res 50, 3646–3651
(erratum appears in Cancer Res 50, 6115).
15 Hauer, J & Anderer, F.A (1993) Mechanism of stimulation of
human natural killer cytotoxicity by arabinogalactan from Larix
occidentalis Cancer Immunol Immunother 36, 237–244.
16 Fischer, S., Scheffler, A & Kabelitz, D (1996) Activation of human gamma delta T-cells by heat-treated mistletoe plant extracts Immunol Lett 52, 69–72.
17 Fischer, S., Scheffler, A & Kabelitz, D (1997) Stimulation of the specific immune system by mistletoe extracts Anticancer Drugs 8 (Suppl 1), S33–S37.
18 Trinchieri, G (1989) Biology of natural killer cells Adv Immunol.
47, 187–376.
19 Colonna, M., Moretta, A., Vely, F & Vivier, E (2000) A high-resolution view of NK-cell receptors: structure and function Immunol Today 21, 428–431.
20 Tomasello, E., Blery, M., Vely, E & Vivier, E (2000) Signaling pathways engaged by NK cell receptors: double concerto for activating receptors, inhibitory receptors and NK cells Semin Immunol 12, 139–147.
21 Moretta, A., Biassoni, R., Bottino, C., Mingari, M.C & Moretta, L (2000) Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis Immunol Today 21, 228–234.
22 Moretta, L., Biassoni, R., Bottino, C., Mingari, M.C & Moretta,
A (2000) Human NK-cell receptors Immunol Today 21, 420–422.
23 Lanier, L.L (2001) On guard-activating NK receptors Nat Immmunol 2, 23–27.
24 Schaller, G., Urech, K & Giannattasio, M (1996) Cytotoxicity of different viscotoxins and extracts from the European subspecies of Viscum album L Phytother Res 10, 473–477.
25 Orru, S., Scaloni, A., Giannattasio, M., Urech, K., Pucci, P & Schaller, G (1997) Amino acid sequence, S-S bridge arrangement and distribution in plant tissues of thionins from Viscum album Biol Chem 378, 989–996.
26 Nitti, G., Orru, S., Bloch, C., Morhy, L., Marino, G & Pucci, P (1995) Amino acid sequence and disulphide-bridge pattern of three gamma-thionins from Sorghum bicolor Eur J Biochem 228, 250–256.
27 Espinosa, E., Belmant, C., Pont, F., Luciani, B., Poupot, R., Romagne´, F., Brailly, H., Bonneville, M & Fournie´, J.J (2001) Chemical synthesis and biological activity of bromohydrin pyr-ophosphate a potent phosphoantigen stimulating human cd T cells J Biol Chem 276, 18337–18344.
28 Jondal, M & Pross, H (1975) Surface markers on human B and T lymphocytes VI Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations Int J Cancer 15, 596–605.
29 Klein, E., Klein, G., Nadkarni, J.S., Nadkarni, J.J., Wigzell, H & Clifford, P (1968) Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines Cancer Res 28, 1300–1310.
30 Deweindt, C., Kerckaert, J.P., Tilly, H., Quief, S., Nguyen, V.C & Bastard, C (1993) Cloning of a breakpoint cluster region at band 3q27 involved in human non-Hodgkin’s lymphoma Genes Chro-mosomes Cancer 8, 149–154.
31 Litwin, V., Gumperz, J., Parham, P., Phillips, J.H & Lanier, L.L (1993) Specificity of HLA class I antigen recognition by human
NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type J Exp Med 178, 1321–1336.
32 DeMars, R., Rudersdorf, R., Chang, C., Petersen, J., Strandtmann, J., Korn, N., Sidwell, B & Orr, H.T (1985) Mutations that impair
a posttranscriptional step in expression of HLA-A and -B anti-gens Proc Natl Acad Sci USA 82, 8183–8187.
33 Robertson, M.J., Cochran, K.J., Cameron, C., Le, J.M., Tantravahi, R & Ritz, J (1996) Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia Exp Hematol 24, 406–415.
34 Gong, J.H., Maki, G & Klingemann, H.G (1994) Characteriza-tion of a human cell line (NK-92) with phenotypical and func-tional characteristics of activated natural killer cells Leukemia 8, 652–658.
Trang 1035 Ferrarini, M., Heltai, S., Toninelli, E., Sabbadini, M.G., Pellicciari,
C & Manfredi, A.A (1995) Daudi lymphoma killing triggers the
programmed death of cytotoxic V gamma 9/V delta 2 T
lymphocytes J Immunol 154, 3704–3712.
36 Perussia, B (2000) Signaling for cytotoxicity Nat Immunol 1,
372–374.
37 Perussia, B., Trinchieri, G & Cerottini, J.C (1979) Functional
studies of Fc receptor-bearing human lymphocytes: effect of
treatment with proteolytic enzymes J Immunol 123, 681–687.
38 Kupfer, A & Singer, S.J (1989) Cell biology of cytotoxic and
helper T cell functions: immunofluorescence microscopic studies
of single cells and cell couples Annu Rev Immunol 7, 309–337.
39 Sidell, N., Schlichter, L.C., Wright, S.C., Hagiwara, S & Golub,
S.H (1986) Potassium channels in human NK cells are involved in
discrete stages of the killing process J Immunol 137, 1650–1658.
40 Hajto, T (1986) Immunomodulatory effects of iscador: a Viscum
album preparation Oncology 43, 51–65.
41 Schink, M (1997) Mistletoe therapy for human cancer: the role of
the natural killer cells Anticancer Drugs 8 (Suppl 1), S47–S51.
42 Stein, G.M & Berg, P.A (1997) Mistletoe extract-induced effects
on immunocompetent cells: in vitro studies Anticancer Drugs 8
(Suppl 1), S39–S42.
43 Mueller, E.A & Anderer, F.A (1990) Chemical specificity of
effector cell/tumor cell bridging by a Viscum album
rhamno-galacturonan enhancing cytotoxicity of human NK cells.
Immunopharmacology 19, 69–77.
44 Jung, M.L., Baudino, S., Ribereau-Gayon, G & Beck, J.P (1990)
Characterization of cytotoxic proteins from mistletoe (Viscum
album L.) Cancer Lett 51, 103–108.
45 Park, J.H., Hyun, C.K & Shin, H.K (1999) Cytotoxic effects of
the components in heat-treated mistletoe (Viscum album) Cancer
Lett 139, 207–213.
46 Florack, D.E & Stiekema, W.J (1994) Thionins: properties, possible biological roles and mechanisms of action Plant Mol Biol 26, 25–37.
47 Bruneton, J (1999) Pharmacognosie 3rd edn Editions Me´dicales Internationales, Paris.
48 Kuttan, G & Kuttan, R (1992) Immunomodulatory activity of a peptide isolated from Viscum album extract (NSC 635, 089) Immunol Invest 21, 285–296.
49 Carrasco, L., Vazquez, D., Hernandez-Lucas, C., Carbonero, P & Garcia-Olmedo, F (1981) Thionins: plant peptides that modify membrane permeability in cultured mammalian cells Eur.
J Biochem 116, 185–189.
50 Hughes, P., Dennis, E., Whitecross, M., Llewellyn, D & Gage, P (2000) The cytotoxic plant protein, beta-purothionin, forms ion channels in lipid membranes J Biol Chem 275, 823–827.
51 Urech, K., Schaller, G., Ziska, P & Giannasttasio, M (1995) Comparative study on the cytotoxic effect of viscotoxin and mistletoe lectin on tumor cells in culture Phytother Res 9, 49–55.
52 Coulon, A., Berkane, E., Sautereau, A.M., Urech, K., Rouge, P & Lopez, A (2002) Modes of membrane interaction of a natural cysteine-rich peptide: viscotoxin A3 Biochim Biophys Acta 1559, 145–159.
53 McConnell, H.M., Owicki, J.C., Parce, J.W., Miller, D.L., Baxter, G.T., Wada, H.G & Pitchford, S (1992) The cytosensor micro-physiometer: biological applications of silicon technology Science
257, 1906–1912.
54 Schlichter, L., Sidell, N & Hagiwara, S (1986) Potassium chan-nels mediate killing by human natural killer cells Proc Natl Acad Sci USA 83, 451–455.